Advances in Alzheimer disease (AD) research during 2010 have identified promising novel diagnostic tools and therapeutic targets for this condition, and suggest that amyloid-β immunotherapy reduces plaque load in patients with AD. A new lexicon for AD has also been proposed.
References
Fukumoto, H. et al. High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716–2726 (2010).
Shankar, G. M. et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837–842 (2008).
He, G. et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467, 95–98 (2010).
Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. Lancet 368, 387–403 (2006).
Rinne, J. O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363–372 (2010).
Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560–574 (2010).
Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 6, 734–746 (2007).
Dubois, B. et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118–1127 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
K. Blennow has received honoraria from Janssen Alzheimer Immunotherapy.
Rights and permissions
About this article
Cite this article
Blennow, K. Paving the way for Alzheimer disease drug development. Nat Rev Neurol 7, 65–66 (2011). https://doi.org/10.1038/nrneurol.2010.214
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.214
- Springer Nature Limited